The Influence of Preoperative Warfarin Medication on Thromboelastography and Blood Transfusion
NCT ID: NCT02191449
Last Updated: 2015-02-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
107 participants
OBSERVATIONAL
2014-06-30
2015-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Tranexamic Acid on Blood Loss After High Tibial Osteotomy
NCT04653623
The Transfusion Triggers in Vascular Surgery Trial
NCT02465125
Antithrombin III Concentrate After Liver Transplantation
NCT04219579
Blood Products Transfusion in Cardiac Surgery After the Implementation of a Coagulation Monitoring System at Patient Bedside: Thromboelastometry Versus Standard Transfusion Protocol
NCT01919840
Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy
NCT02238444
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients who have atrial fibrillation undergoing cardiac surgery with Maze-operation were included.
The following exclusion criteria are applied:
1. Patients who have taken medicine related to coagulation (such as antiplatelets like aspirin and clopidogrel) except warfarin or bridged heparin
2. Patients whose laboratory values could not be confirmed by medical records review.
Patients were categorized by two groups.
1. W group: patients on atrial fibrillation who have taken warfarin for p.o medication.
2. C group: patients on atrial fibrillation who have not taken warfarin for p.o medication.
Using blood sample, authors examined as follows:
1. Preoperative (maximum 5days before operation) and postoperative (30min after ICU admission) coagulation values with haematologic values: PT/aPTT, INR, Hb, Hct, platelet levels.
2. ROTEM values at 30min after anaesthetic induction and 30min after ICU admission: Clotting time (CT), clot formation time (CFT), maximum clot firmness (MCF), maximum lysis (ML)
3. Intraoperative (during operation) and postoperative (during admission, an expected average of 5 weeks) total transfusion amount: RBC, FFP, PC, cryoprecipitate.
4. Post operative 24 hr bleeding amount in the chest tube drain bottle.
5. The duration (maximum 2 weeks) of warfarin discontinuation. (in W group)
Statistical analysis was performed using unpaired t-test and chi-square test to compare patients demographic data and other parameters. To determine the relationship of INR and ROTEM parameters with bleeding amount and transfusion amount, multiple linear regression model that accounted for all confounder variables was used. For each factor in the multiple regression model, variables with a p value of less than 0.10 were kept in the final model. The data was analyzed using the program Statistical Package for the Social Sciences ver. 18.0 (SPSS Inc, Chicago, USA). A value of p \< 0.05 was considered statistically significant.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* W group : Patients who have had warfarin therapy before operation due to treat Atrial fibrillation
* C group : Patients who have not had warfarin therapy before operation
Exclusion Criteria
* 2\. Patients whose laboratory values could not be confirmed by medical records review.
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Konkuk University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Seong-Hyop Kim, M.D,Ph.D
Role: PRINCIPAL_INVESTIGATOR
Konkuk University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Konkuk University Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KUH1160068
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.